Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Acquired by Walleye Capital LLC

Walleye Capital LLC increased its holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 253.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 328,417 shares of the company's stock after purchasing an additional 235,548 shares during the period. Walleye Capital LLC owned approximately 0.56% of Cullinan Therapeutics worth $5,498,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of CGEM. Amalgamated Bank raised its position in shares of Cullinan Therapeutics by 97.3% in the third quarter. Amalgamated Bank now owns 1,768 shares of the company's stock valued at $30,000 after buying an additional 872 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Cullinan Therapeutics by 73.3% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,883 shares of the company's stock valued at $155,000 after purchasing an additional 3,758 shares during the period. Arizona State Retirement System bought a new stake in shares of Cullinan Therapeutics during the second quarter worth about $182,000. Squarepoint Ops LLC bought a new stake in shares of Cullinan Therapeutics during the second quarter worth about $186,000. Finally, China Universal Asset Management Co. Ltd. grew its position in Cullinan Therapeutics by 64.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,151 shares of the company's stock worth $187,000 after purchasing an additional 4,380 shares in the last quarter. 86.31% of the stock is currently owned by institutional investors.

Cullinan Therapeutics Trading Down 2.1 %

Shares of Cullinan Therapeutics stock traded down $0.28 on Monday, hitting $13.17. 682,275 shares of the company traded hands, compared to its average volume of 650,595. The stock's 50 day moving average price is $15.57 and its 200-day moving average price is $17.76. The company has a market cap of $766.86 million, a PE ratio of -4.74 and a beta of -0.12. Cullinan Therapeutics, Inc. has a 52 week low of $7.64 and a 52 week high of $30.19.

Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.69) earnings per share for the quarter, topping analysts' consensus estimates of ($0.78) by $0.09. As a group, research analysts anticipate that Cullinan Therapeutics, Inc. will post -3.12 EPS for the current fiscal year.

Insider Transactions at Cullinan Therapeutics

In other Cullinan Therapeutics news, insider Jennifer Michaelson sold 8,000 shares of the company's stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $15.64, for a total value of $125,120.00. Following the completion of the transaction, the insider now owns 107,942 shares in the company, valued at $1,688,212.88. This represents a 6.90 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 6.07% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently commented on CGEM shares. UBS Group began coverage on shares of Cullinan Therapeutics in a research note on Thursday, October 24th. They set a "buy" rating and a $30.00 price target on the stock. HC Wainwright reissued a "buy" rating and issued a $28.00 price target on shares of Cullinan Therapeutics in a report on Wednesday, October 16th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $36.00 target price on shares of Cullinan Therapeutics in a research report on Wednesday, September 18th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, Cullinan Therapeutics presently has an average rating of "Buy" and a consensus price target of $31.67.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.